The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2021 | Relevance of current prognostication and prediction markers for CLL with new targeted therapies
Richard Rosenquist, MD, PhD, Karolinska Institute, Sweden, Stockholm, discusses current genetic markers used for the prediction and prognostication of chronic lymphocytic leukemia (CLL) with regards to chemoimmunotherapy and new targeted therapies. Whilst Prof. Rosenquist explains that molecular tests used to detect p53 aberrations are still important, he argues that the prognostic impact of IGH mutation status is becoming less important with novel therapies. Prof. Rosenquist also comments on the impact of complex karyotypes as a prognostic marker. Finally, Prof. Rosenquist discusses the role of new genetic markers, such as BCR subset 2, which show that certain groups of patients do not benefit from chemoimmunotherapy. This interview took place at the 19th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held virtually in 2021.
